Fast Facts


Financial Fast Facts

Revenue Highlights 2Q18

Financial Overview 2Q18

Net Debt & Leverage Ratio4

Capital Deployment Priorities

Expect free cash flow in mid-$600
million-range in FY18*

Business development

  • Blood divestiture, Cynosure acquisition shifted portfolio toward higher growth segments
  • Tuck-in acquisitions
  • Accretive to revenue, EPS growth rates
  • Attractive ROIC
  • Leveraging existing sales channels

Opportunistic share repurchases

  • ~$200 million board authorization remaining

Revenue5

1H'18 Divisional Revenue by Geography

Non-GAAP EPS5

% Operating Margin

ROIC7

‛18 Financial Guidance

*Excluding one-time tax expenses.

4. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA.
5. Total non-GAAP revenue and EPS growth as reported with the exception of FY14, which excludes ~$20 million one-time revenue contribution from restructuring of Roka license, which increased operating margin and added $0.05 to EPS. Reconciliations to GAAP are available in quarterly financial releases and at Hologic.com/investors.
6. Based on midpoint of guidance provided by press release on 5/2/18. Presentation here is not, and should not be construed as, re-affirmation of guidance.
7. ROIC on a Trailing Twelve Month basis, defined as adjusted net operating profit after tax divided by average net debt plus stockholders’ equity.